Allergy & Inflammation Research, Division of Infection, Inflammation & Immunity, School of Medicine, Southampton University and General Hospital, Southampton, Hampshire, UK.
Immunol Rev. 2011 Jul;242(1):205-19. doi: 10.1111/j.1600-065X.2011.01030.x.
The adoption of the concept that asthma is primarily a disease most frequently associated with elaboration of T-helper 2 (Th2)-type inflammation has led to the widely held concept that its origins, exacerbation, and persistence are allergen driven. Taking aside the asthma that is expressed in non-allergic individuals leaves the great proportion of asthma that is associated with allergy (or atopy) and that often has its onset in early childhood. Evidence is presented that asthma is primarily an epithelial disorder and that its origin as well as its clinical manifestations have more to do with altered epithelial physical and functional barrier properties than being purely linked to allergic pathways. In genetically susceptible individuals, impaired epithelial barrier function renders the airways vulnerable to early life virus infection, and this in turn provides the stimulus to prime immature dendritic cells toward directing a Th2 response and local allergen sensitization. Continued epithelial susceptibility to environmental insults such as viral, allergen, and pollutant exposure and impaired repair responses leads to asthma persistence and provides the mediator and growth factor microenvironment for persistence of inflammation and airway wall remodeling. Increased deposition of matrix in the epithelial lamina reticularis provides evidence for ongoing epithelial barrier dysfunction, while physical distortion of the epithelium consequent upon repeated bronchoconstriction provides additional stimuli for remodeling. This latter response initially serves a protective function but, if exaggerated, may lead to fixed airflow obstruction associated with more severe and chronic disease. Dual pathways in the origins, persistence, and progression of asthma help explain why anti-inflammatory treatments fail to influence the natural history of asthma in childhood and only partially does so in chronic severe disease. Positioning the airway epithelium as fundamental to the origins and persistence of asthma provides a rationale for pursuit of therapeutics that increase the resistance of the airways to environmental insults rather than concentrating all effort on suppressing inflammation.
采用哮喘主要是一种与辅助性 T 细胞 2(Th2)型炎症相关的疾病的概念,导致了广泛认为其起源、加重和持续存在是过敏原驱动的。将非过敏个体表达的哮喘排除在外,剩下的就是与过敏(或特应性)相关的大部分哮喘,而且这种哮喘通常在儿童早期发病。有证据表明,哮喘主要是一种上皮疾病,其起源及其临床表现与改变上皮物理和功能屏障特性有关,而与过敏途径无关。在遗传易感个体中,上皮屏障功能受损使气道容易受到早期生命病毒感染,而这反过来又刺激不成熟的树突状细胞向 Th2 反应和局部过敏原致敏方向发展。上皮继续易受环境刺激,如病毒、过敏原和污染物暴露,以及受损的修复反应,导致哮喘持续存在,并为炎症和气道壁重塑的持续提供介质和生长因子微环境。上皮层网状层基质的沉积增加为持续的上皮屏障功能障碍提供了证据,而反复支气管痉挛导致的上皮物理扭曲为重塑提供了额外的刺激。这种反应最初起到保护作用,但如果过度,可能导致与更严重和慢性疾病相关的固定气流阻塞。哮喘起源、持续和进展的双重途径有助于解释为什么抗炎治疗不能影响儿童哮喘的自然史,而在慢性严重疾病中只能部分影响。将气道上皮作为哮喘起源和持续存在的基础,为寻找增加气道对环境刺激的抵抗力的治疗方法提供了理由,而不是将所有努力都集中在抑制炎症上。